Supplement: Oncology November 2011

Publication
Article

The Future of Treatment for Patients With Relapsed/Refractory Multiple MyelomaThe supplement and associated publication costs were funded by Onyx Pharmaceuticals

The Future of Treatment for Patients With Relapsed/Refractory Multiple MyelomaThe supplement and associated publication costs were funded by Onyx Pharmaceuticals

 

The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). As the treatment landscape has evolved, it has become readily apparent that the available therapies have different tolerability profiles depending on patient and disease characteristics.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
Related Content